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OBJECTIVE – We conducted a nested case-control investigation to examine if elevated 
baseline concentrations of cystatin-C predicted progression from normoglycaemia to 
prediabetes over 6 years of follow-up from the Western New York Health Study.  
RESEARCH DESIGN AND METHODS – 1,455 participants from the Western New 
York Health Study, free of type 2 diabetes and known cardiovascular disease at baseline 
(1996-2001), were reexamined in 2002-2004.  An incident case of prediabetes was 
defined as one with fasting glucose below 100 mg/dl at the baseline examination and ≥ 
100 mg/dl and ≤  125 mg/dl at the follow-up examination. All cases (n=91) were matched 
1:3 to control participants based upon sex, race/ethnicity and year of study enrollment.  
All controls had fasting glucose levels < 100 mg/dl at both baseline and follow-up 
examinations. Cystatin-C concentrations and the urinary albumin to creatinine ratio were 
measured from frozen (-196 Cº) baseline blood and urine samples. Serum creatinine 
concentrations were available from the baseline examination. 
 RESULTS –Multivariate conditional logistic regression analyses adjusted for age, 
baseline glucose level, HOMA-IR, body mass index, hypertension, eGFR, cigarette 
smoking, and alcohol use revealed a significantly increased risk of progression to 
prediabetes among those with elevated baseline concentrations of cystatin-C (Odds Ratio, 
95% CI: 3.04, 1.34, 6.89) (upper quintile vs. the remainder).  Results of secondary 
analyses that considered hs-CRP, IL-6, E-selectin, or sICAM did not alter these results. 
CONCLUSIONS - These results suggest that early renal impairment indexed with 
cystatin-C imparted a three-fold excess risk of progression to prediabetes in this study 
population.   
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Recent evidence from randomized clinical trials (1,2) among people with prediabetes 
have provided convincing evidence that early intervention can significantly delay or 
prevent the progression to type 2 diabetes.  The identification of those with prediabetes is 
assuming greater importance (3) especially in light of the fact that approximately 35 
million adults aged 40-74 years old in the United States have prediabetes defined as 
impaired fasting glucose (4).  Microalbuminuria occurs frequently in nondiabetic subjects 
and places them at increased risk for cardiovascular disease (5-7).  The mechanisms 
behind this observation are poorly understood, however.  Albuminuria may reflect 
underlying vascular damage (8), hypertension (9, 10) endothelial dysfunction (11, 12) 
and/or low-grade inflammation (13). 
 
A large percentage of type 2 individuals pass through a period of prediabetes (14) and 
may experience early renal dysfunction e.g., a glomerular filtration rate (GFR) above 60  
ml/minute per 1.73m2.  Currently used estimating equations are poor at identifying early 
renal impairment and better indices are of great interest (15, 16).   Recently, several 
studies have suggested that cystatin-C levels may be a more sensitive marker of early 
renal impairment than either albuminuria or serum creatinine concentration (17-20).  
Therefore, a better understanding of a putative role for cystatin-C in the etiology of 
prediabetes could shed light on the renal/heart disease connection (21).  Given the 
reported superiority of cystatin C over conventional measures of renal function, we 
hypothesized that cystatin-C would predict progression to prediabetes independent of 
serum creatinine or estimated GFR.  We also investigated the role of intervening 
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mechanisms including hypertension, insulin resistance, endothelial dysfunction and 
inflammation. 
 
RESEARCH DESIGN AND METHODS 
Participants 
 
The study design and methodology of this community-based investigation have 
been previously published (22, 23).  Briefly, participants in the this report were 
originally enrolled as healthy control subjects in the Western New York Study, an 
epidemiologic case-control investigation of alcohol intake patterns and risk of 
cardiovascular disease in Erie and Niagara Counties, New York conducted in 
1996-2001.  The initial cohort of control participants was randomly selected from 
drivers license lists for those under age 65, and from the Health Care Finance 
Administration rolls for those aged 65-79.  In 2001-2004 we conducted the first 
follow-up of the apparently healthy MI control group. Eligible participants for the 
follow-up study were men and women aged 39-79 years selected from the 
baseline examination without known clinical cardiovascular disease (self-reported 
MI, angina or revascularization surgery) or type 2 diabetes mellitus (measured 
fasting plasma glucose > 125 mg/dl or self report and taking medication) and who 
were capable of completing the current study protocol (n=2652).  Exclusion 
criteria also included self-report of a medical condition that would prohibit 
participation (e.g., all cancers except skin cancer, type 1 diabetes, physical or 
mental impairment), permanent change in residence out-of-state, deceased, or 
inability to contact and determine eligibility. This left 2139 persons eligible for 
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this examination of whom 1455 completed the full clinic protocol (68.0% 
response rate). Compared to those that refused, the participants were less likely to 
smoke and have more formal education.  There were no significant differences in 
fasting glucose concentrations or BMI or sex ratio (data not presented).   The 
mean follow-up time was 5.9 years (SD = 0.8 yrs).   The protocol was approved 
by the University at Buffalo Health Science Institutional Review Board and all 
participants provided written informed consent prior to participation. 
 
Study Protocol 
At both the baseline and six-year follow-up examinations all participants received 
a clinical examination that included resting blood pressure, measures of height, 
weight, and waist girth according to standardized protocols (24).  Hypertension 
was defined as a systolic pressure greater than or equal to 140 mmHg or a 
diastolic pressure greater than or equal to 90 mmHg or use of antihypertensive 
medications regardless of blood pressure level.  Study subjects also provided a 
fasting (at least 10 hrs overnight) blood sample and asked to refrain for 24 hours 
from smoking or vigorous physical activity. Several standardized questionnaires 
were administered including cigarette use (never, ever) and lifetime pack-years of 
smoking,  physical activity (Stanford 7-Day Recall), alcohol use, general health 
and well-being, personal and family health history, medication use and 
socioeconomic status.  Participants were instructed to bring all medications to the 
clinic visits permitting identification of oral medications as well as insulin use.  A 
positive family history of type 2 diabetes was defined as a positive report in a first 
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degree relative.  An incident case of prediabetes was defined as one with fasting 
glucose below 100 mg/dl at the baseline examination and ≥ 100 mg/dl and ≤ 125 
mg/dl at the follow-up examination. All cases (n=91) were matched 1:3 to control 
participants based upon sex, race/ethnicity and year of study enrollment.  All 
controls had fasting glucose levels < 100 mg/dl at both baseline and follow-up 
examinations. 
  
Laboratory Methods 
Fasting glucose concentrations were determined by the glucose oxidase method 
(Beckman instruments, Fullerton, CA).  The interasssay coefficient of 
determination was below 5%. After identification of those who progressed (cases) 
or not (controls) to prediabetes, the baseline aliquots of serum or plasma were 
retrieved and sent by overnight courier for analysis.  Cystatin-C was measured 
using the BN II nephelometer (Dade Behring Inc., Deerfield, IL) utilizing a 
particle enhanced immunonepholometric assay (N Latex Cystatin C).  This assay 
range was 0.195 to 7.330 mg/dl.  The intra-assay CV% was 2.0-2.8% and the 
inter-assay range was 2.3-3.1%.  Interleukin-6 was measured by ultra-sensitive 
ELISA (R&D Systems, Minneapolis, MN.  Using this method, we have 
determined a routine CV in the lab of 6.3%.   Soluble E-Selectin (E-Selectin) was 
measured using a high sensitivity quantitative sandwich enzyme (Parameter 
Human sE-Selectin Immunoassay; R&D Systems, Minneapolis, MN).   Intra-
assay and inter-assay CVs range from 4.7 – 5.0% and 5.7 – 8.8%, respectively.  
Human Soluble Intercellular Adhesion Molecule-1(sICAM) was measured by an 
 6
ELISA assay (Parameter Human sICAM-1 Immunoassay; R&D Systems, 
Minneapolis, MN).   The laboratory CV was 5.0%. High sensitivity C-reactive 
protein was measured using the BNII nephelometer from Dade Behring utilizing a 
particle enhanced immunonepholometric assay.   Intra-assay CVs range from 2.3 
– 4.4% and inter-assay CVs range from 2.1 – 5.7%.    Fasting insulin was assayed 
from a kit provided by Linco Research, Inc that has minimal cross reactivity with 
human proinsulin.  The assay has a lower detection limit of 2 µU/ml with 
interassay CV% of 3.6-8.4% and intrassay CV% from 2.2-4.4%.  The homeostasis 
model of insulin resistance (HOMA-IR) was calculated as fasting glucose x 
fasting insulin /22.4 (25).  A frozen spot urine was also retrieved and utilized for 
the assessment of the albumin to creatinine (ACR) ratio.  Collections were done in 
the morning of the baseline visit and stored on liquid nitrogen.  Albumin was 
assayed with a nephelometric immunoassay using a monospecific antiserum to 
human albumin.  Creatinine concentration was determined using the modified 
Jaffe method.  The urinary albumin to creatinine ratio (ACR mg albumin / g 
creatinine) was calculated and utilized as a surrogate of albumin excretion rate 
(26).   Intraclass correlation coefficients among duplicate samples exceeded 0.95.  
Over ninety-four percent of the values were below 30 mg/g.  Glomerular filtration 
rate was estimated (eGFR) using the four variable formula from the Modification 
of Dietary Restriction in Diabetes Study (27, 28).  This formula is: eGFR = 186.3 
x (Serum creatinine concentration -1.154) x (age-0.203) x 1.212 (if black) x 0.742 (if 
female). 
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Statistical Procedures 
For this report, data were compared between cases and controls with chi-square 
tests or unpaired t-tests as appropriate.   Multivariate conditional logistic 
regression models (conditioned on the matching variables) were utilized to 
estimate the effect of elevated cystatin-C on prediabetic status after adjustment for 
age (model 1) and also after adjustment for several explanatory variables (model 
2).  We a priori compared the top quintile of cystatin-C to the remaining 80 
percent determined by the distribution of cystatin-C among the controls. The top 
quintile range was 1.02-1.70 mg/dl.  For ACR, we chose a cutpoint of 20, and for 
serum creatinine and eGFR, we split the distribution at the median value of the 
controls (0.8 mg/l and 83.3 ml per minute per 1.73 m2).  There were too few 
people to meaningfully examine the effect of higher clinical cutpoints.   
Likelihood ratio tests were conducted to test for statistical interactions by 
comparing the log likelihood between the two nested models, one with only the 
main effects, and the other with both the main effects and the interaction terms in 
the model.  No significant effect-modification was noted.  All statistical tests were 
two-sided and a p-value of < 0.05 was considered statistically significant.  
Analyses were carried out using the SPSS for Windows version 14.0 (Chicago, 
IL).   
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RESULTS 
Table 1 presents selected characteristics at baseline for cases and controls.  
There were 91 cases of prediabetes that were matched with 273 control 
participants.  Those who progressed to become cases of prediabetes were 
significantly older, more obese and heavier lifetime smokers than the controls 
(P < 0.05 for each).   Cases were also significantly more insulin resistant at 
baseline and displayed higher mean concentrations of cystatin-C.  No 
significant differences were observed for serum creatinine or eGFR.  Fasting 
plasma glucose was higher among the cases than controls (94.3 vs 90.5 mg/dl; 
P < 0.001).  Cases had significantly less formal education and a higher 
prevalence of a family history of diabetes, and were more likely to be 
hypertensive at the baseline examination.  Compared to the controls, cases 
were more likely to have been smokers consumers of alcohol (P < 0.05). 
 
Table 2 presents the results of conditional logistic regression also adjusted for 
age.  As shown, a positive family history of type 2 diabetes, hypertension, 
cigarette smoking, and HOMA-IR were each related to prediabetic status.  A 
BMI  ≥ 27 kg/m2  was associated with a 62 percent excess risk, although the 
95% CI included unity.  Neither serum creatinine nor ACR were found to 
predict prediabetic status.  Consideration of continuous forms for these 
variables also provided no evidence of association with prediabetic status.   
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The results of the multiple conditional logistic regression analyses for cystatin-
C and odds of developing prediabetes are displayed in Table 3.  Models were 
conditioned on the matching variables of sex, race, and year of study 
enrollment.  Model one was further adjusted for age and model 2 was fully-
adjusted for age and several of the explanatory variables shown in table 2 
including eGFR.  Comparing the highest quintile of cystatin-C to the lowest 
80% revealed an age-adjusted odds ratio of 5.08 (95%CI: 2.69, 9.58).  After 
consideration of the putative risk factors for prediabetes in model 2, the odds 
ratio was attenuated to 3.04 (95% CI: 1.34, 6.89) but remained highly 
statistically significant (P ≤ 0.01).  No change in the effect size for cystatin-C 
was observed when serum creatinine (or ACR) was substituted for eGFR. 
 
In order to investigate possible intervening mechanisms, we examined the 
association between cystatin-C, serum creatinine, urinary ACR, and several 
biomarkers of inflammation (hs-CRP and IL-6) and endothelial dysfunction 
(E-selectin and sICAM) among the control group (table 4).  As shown, 
cystatin-C was significantly, though modestly associated with hs-CRP, E-
selectin, sICAM, and IL-6 (P < 0.001 for each).  Cystatin-C was not 
significantly correlated with ACR (rs = -0.007) but was significantly correlated 
with serum creatinine (rs = 0.446; P < 0.001) and eGFR (rs = -0.384; P <0.01).  
Secondary analyses were performed where biomarkers of inflammation or 
endothelial dysfunction were each considered one by one.  Neither adjustment 
for E-selectin, nor sICAM had virtually any effect on the results.  
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Consideration of hs-CRP, IL-6 or eGFR likewise failed to materially alter the 
original findings.   
 
CONCLUSION 
In this investigation, we found an approximate three-fold increased risk of 
progression to prediabetes among those in the highest quintile of cystatin-C in 
a population free of diabetes and known cardiovascular disease.  This 
association was independent of obesity, baseline glucose, eGFR (or serum 
creatinine), ACR, and other explanatory variables.  These results extend 
previous observations for cardiovascular disease (17-20, 29) to include the 
early diabetic stage. 
 
Several studies have examined proteinuria or microalbuminuria in relation to 
future health events in populations with type 1 diabetes, type 2 diabetes, and 
apparently healthy subjects.  Proteinuria is a risk factor for end-stage renal 
disease among those with type 1 diabetes, and microalbuminuria has been 
associated with increased CVD mortality among both nondiabetic and type 2 
diabetic persons (30-33).  Cystatin C is also raised in the diabetic state but has 
been related to increased risk of mortality independent of diabetic status (18). 
 
The results of this study support the hypothesis that cystatin – C may be 
elevated in advance of the onset of clinical diabetes and further suggest a 
preclinical stage of renal impairment that presages or develops in parallel with 
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the prediabetic condition (34).  Our results also document the predictive power 
of cystatin C in the context of other risk factors for hyperglycemia and indicate 
that cystatin-C was a more powerful predictor than the traditional measures of 
serum creatinine or the ACR in a population with modest renal impairment.  It 
is well known, however, that the estimated GFR is less precise among those 
with a GFR above 60 ml per minute per 1.73 m2 of body surface area and thus 
has a limited prognostic value in a generally healthy population such as ours, 
thus we can not rule out that imprecision in the eGFR may still confound these 
results.  Serum creatinine values also have limited power to accurately reflect 
underlying renal function among those with only modest impairment of kidney 
disease.   These findings suggest that cystatin-C may be a more useful marker 
of renal impairment in populations with mild renal impairment.  
The prevalence of hypertension at baseline was higher among the future case 
group than the matched controls.  We do not know whether blood pressure rose 
before or concomitantly with cystatin C levels.   Cigarette smoking and 
intensity of smoking were also higher among cases than controls.  Smoking 
has been identified in some studies to predict microalbuminuria among type 1 
individuals (30).  Hyperinsulinemia/insulin resistance has also been associated 
with albuminuria in several reports (31- 33).  Our results confirmed these 
associations but suggest further that the effect of cystatin C on risk of 
progression was largely independent of hypertension, smoking and HOMA-IR.  
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Preclinical kidney disease has been suggested to be related to underlying 
processes unrelated to the kidney per se (34).  Our data indicated that cystatin-
C was significantly correlated with several markers of inflammation including 
hs-CRP and IL-6.  However in secondary analyses that considered these 
biomarkers, the results remained unaltered.  The same held true for markers of 
endothelial function (E-selectin and sICAM (data not shown).  These results 
are consistent with findings from the Cardiovascular Health Study (35) but 
suggest further that the effect of cystatin-C on risk of progression to 
prediabetes cannot be solely explained by inflammation or endothelial 
dysfunction.  We did not find an association between urinary ACR and 
cystatin-C, likely due to the narrow distribution of ACR in our study 
population and/or the use of a single casual urine sample.   
 
Several limitations are deserving of comment.  We did not use an oral glucose 
tolerance test thus some of the study participants classified as prediabetic cases 
at the follow-up examination, may have undetected type 2 diabetes (36).  
However, fasting glucose measures are more highly correlated over time than 
the 2-hour postchallenge glucose level and upon repeat testing many with 
newly detected type 2 diabetes are found to “revert” to either impaired glucose 
tolerance or normal (37-39).  We also had only single measures of both 
cystatin-C and glucose.  This random error would serve however, to bias our 
results towards the null.  The strengths of the study include the selection of a 
community-based population, detailed measures of several important 
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covariates, and the assessment of possible intermediate factors including 
hypertension, smoking, insulin resistance, inflammation, and endothelial 
dysfunction.  Our results, however, need to be replicated, particularly among 
minority populations. Although observational studies cannot prove causality, 
the magnitude of the effect size and statistical control for many covariates 
make our findings compelling and important. 
 
Cystatin-C has been shown recently to predict incident coronary heart disease 
events (40), suggesting that the renal/heart disease connection may share 
common mechanisms.  Our findings provide an important new avenue for 
future research suggesting that mild renal impairment may occur early in the 
natural history of diabetes.  The possibility that cystatin C may also predict 
type 2 diabetes remains to be tested, but if proved correct, raises intriguing 
possibilities for prevention and treatment as it might be fruitful to look for 
markers of renal impairment early in the course of hyperglycemia that could be 
modified by lifestyle and hygienic measures. 
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Table 1. Selected Baseline characteristics among prediabetic cases and 
matched controls 
 
 Cases         Controls P-value 
 n=91       n=273  
  Mean SD Mean SD  
Age (years) 57.9 11.0 54.2 10.8 0.005 
BMI (kg/m2) 28.12 5.2 26.91 4.6 0.040 
Waist (cm) 91.9 13.46 87.2 12.5 0.003 
Abdominal height (cm) 21.2 3.2 20.1 3.2 0.005 
Lifetime total pack years 
cigarettes 14.4 22.6 9.1 15.81 
0.037 
Physical Activity (METS in past 
7 days) 259.1 46.3 262.4 49.8 
0.574 
Glucose (mg/dl) 94.2 4.3 90.4 5.4 <0.001 
HOMA 3.45 1.70 2.95 1.57 0.011 
ACR (mg/g) 12.06 37.48 7.32 10.45 0.256 
Cystatin C (mg/l) 1.05 0.23 .90 0.15 <0.001 
eGFR1  (ml per minute per 
1.73 m2) 83.0 17.7 83.6 17.0 
0.631 
Serum creatinine (g/l) 0.89 0.18 0.88 0.17 0.579 
 %  %   
Male Gender (%) 42.9  42.9  ------ 
Whites (%) 95.6  95.6  ------ 
Education >12 years (%) 59.3  71.1  0.038 
Family history of diabetes (%) 42.9  26.7  0.005 
Hypertension (%) 38.6  20.8  0.001 
Family history of HTN (%) 39.3  35.7  0.549 
      
Smoking (%)     0.017 
   Never 48.4  51.8   
   Ever 51.6  48.2   
      
      
Drinking (%)     0.028 
   Abstainer 7.7  9.7   
   Non-current 30.8  20.4   
   Non-daily 50.5  64.7   
   Daily 11.0  5.2   
      
 
------ Matching Variable 
 
1 eGFR = 1.86  x (serum creatinine)-1.154 x (Age)-0.203 x (0.742 if female) x (1.21 if black) 
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Table 2.   Age-adjusted Odds ratios (95% CI) for Progression to Prediabetes According to 
Selected Baseline Characteristics 
 
 Cases Controls 
 N % N % OR ⁪ 95% CI ⁪ 
       
       
BMI (kg/m2)       
<27 43 47.8  161 60.3 1.00  
≥27 47 52.2  106 39.7 1.62 0.99, 2.66 
       
Family history of diabetes:       
No 48 57.1  189 73.3 1.00  
Yes 36 42.9  69 26.7 1.85* 1.12, 3.07 
       
Smoking:       
Never 34 37.4  141 51.8 1.00  
Ever 57 62.6  131 48.2 1.95* 1.15, 3.07 
       
Current alcohol drinker:       
No 35 38.5  81 30.1 1.00  
Yes 56 61.5  188 69.9 0.65 0.38, 1.12 
       
Hypertension: 
 
      
No 54 61.4  213 79.2 1.00  
Yes 34 38.6  56 20.8 2.39** 1.35, 4.22 
       
Physical Activity  
(Total METS in past 7 days) 
      
< Median 52 57.1  136 50.0 1.00  
≥ Above median 39 42.9  136 50.0 0.82 0.49, 1.37 
       
HOMA-IR         
1 (low) 15 17.0  90 33.2 1.00  
2 35 39.8  91 32.6 2.19* 1.12, 4.28 
3 (high) 38 42.2  90 33.2 2.75* 1.37, 5.54 
       
ACR (mg/g)       
<20 78 92.9  232 94.3 1.00  
≥20   6 7.1  14 5.7 0.94 0.34, 2.60 
       
eGFR       
< median  52 57.1 134 49.1 1.00  
≥ median 39 42.9 139 50.9 0.84 0.50, 1.40 
       
Serum Creatinine (g/l)       
< median  39 42.9 130 47.6 1.00 0.66, 2.11 
≥ median 52 57.1 143 52.4 1.18  
 
 ⁪ OR and 95% CI from Conditional Logistic Regression adjusted for age. Cases and controls matched on year of baseline 
interview, gender, race, and year of study enrollment. 
 
* p<.05, ** p<.01 
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Table 3.  Multivariate Odds ratios (95% CI) for Progression to Prediabetes According to Baseline 
Quintile of Cystatin-C (top 20% vs lowest 80%).  
 
 Cases Controls Model 1 Model2 
 N % N % OR ⁪ 95% CI ⁪ OR ⁪ 95% CI ⁪ 
         
Cystatin-C 
(mg/l) 
        
Lowest 80% 42 46.7 218 79.9 1.00  1.00  
Top 20 % 48 53.3  55 20.1 5.08*** 2.69, 9.58 3.04** 1.34, 6.89 
         
 
⁪⁪ OR and CI from conditional logistic regression using matched cases and controls.  
All models are conditioned on sex, race, and year of study enrollment. 
 
Model 1 adjusted for age. 
Model 2 adjusted for age, BMI (kg/m2), family history of diabetes (no,yes), current smoker (never,ever), lifetime pack-
years, fasting glucose (mg/dl), current drinker (no,yes), baseline hypertension(no,yes), HOMA-IR, and eGFR  
 
** p<.01, *** p<.001 
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Table 4. Spearman Correlation Coefficients Between Cystatin-C and Selected 
Biomarkers for Inflammation and Endothelial Dysfunction Among the Control Group 
 
 
 
 
Cystatin-C 
Age 0.377***
Hs-CRP 0.196** 
E-selectin 0.179** 
sICAM 0.294** 
IL-6 0.243** 
Serum creatinine 0.446***
eGFR -0.384** 
ACR -0.007 
 
** p< 0.01   
*** p< 0.001 
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